Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Cash & Equivalents (2019 - 2025)

Bioadaptives' Cash & Equivalents history spans 7 years, with the latest figure at $59273.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 35.04% year-over-year to $59273.0; the TTM value through Sep 2025 reached $59273.0, up 35.04%, while the annual FY2024 figure was $137470.0, 126.19% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $59273.0 at Bioadaptives, down from $210582.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $210582.0 in Q2 2025 and bottomed at $235.0 in Q2 2024.
  • The 5-year median for Cash & Equivalents is $44450.0 (2022), against an average of $60932.4.
  • The largest annual shift saw Cash & Equivalents plummeted 99.41% in 2024 before it skyrocketed 89509.36% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $82936.0 in 2021, then plummeted by 69.37% to $25405.0 in 2022, then skyrocketed by 139.23% to $60776.0 in 2023, then soared by 126.19% to $137470.0 in 2024, then tumbled by 56.88% to $59273.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Cash & Equivalents are $59273.0 (Q3 2025), $210582.0 (Q2 2025), and $39564.0 (Q1 2025).